Cell Source, Inc.
Cell Source, Inc.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | |||||
Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | |||||
Assets Current | |||||||||||||||||
Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Accounts Payable Current | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | |||||
Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | |||||
Interest Payable Current | - | - | - | 0 | - | - | - | - | - | 1 | 1 | 1 | |||||
Deferred Compensation Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Notes Payable Current | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | |||||
Liabilities Current | |||||||||||||||||
Notes Payable Related Parties Classified Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Convertible Debt Current | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | |||||
Derivative Liabilities Current | - | - | - | - | 0 | 0 | - | - | - | - | - | - | |||||
Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | |||||
Dividends Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities | 20 | 19 | 19 | 18 | 17 | 16 | 16 | 15 | 14 | 13 | 12 | 11 | |||||
Stockholders Equity | |||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | -20 | -19 | -19 | -17 | -17 | -16 | -16 | -15 | -14 | -13 | -12 | -11 | |||||
Additional Paid In Capital | 27 | 28 | 27 | 27 | 26 | 26 | 25 | 24 | 24 | 24 | 23 | 23 | |||||
Retained Earnings Accumulated Deficit | -48 | -46 | -46 | -44 | -43 | -42 | -41 | -39 | -38 | -36 | -35 | -34 | |||||
Liabilities And Stockholders Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | |||||
Common Stock Shares Issued | 45 | 45 | 43 | 42 | 41 | 40 | 38 | 38 | 37 | 36 | 0 | 35 | |||||
Shares Outstanding | 45 | 45 | 43 | 42 | 41 | 40 | 38 | 38 | 37 | 36 | 35 | 35 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 0.00% | 13.41% | - | - | - | - | - | - | - | - | - | - |
| 2024 | 53650.00% | 49900.00% | 37400.00% | 2.56% | -28.21% | 56.95% | 15.25% | -31.36% | -47.46% | 14.94% | 9.47% | 12.21% |
| 2023 | 0.00% | 24714.81% | 25455.55% | 24714.81% | 25455.55% | 13233.33% | -34.78% | -33.33% | -28.99% | 0.00% | 46775.00% | 49900.00% |
| 2022 | - | - | - | - | - | - | - | - | - | 28.57% | 28471.43% | 27985.72% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Cell Source, Inc. (CLCS) — SEC Financial Statements & Analysis
Cell Source, Inc. (CLCS) is a pharmaceutical preparations company, incorporated in NV. Cell Source, Inc. trades on OTC as: CLCS. Based on its latest SEC filing (Form 10-Q, period ending 2025-03-31), Cell Source, Inc. reported a Price-to-Book (P/B) ratio of -0.72x (TTM), at a market cap of $14.40M. Figures below are sourced from SEC EDGAR, as-filed.
- P/B TTM
- -0.72x
- Market Cap
- $14.40M
Data as of 2025-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cell Source, Inc. in?
Cell Source, Inc. (CLCS) operates in the Pharmaceutical Preparations industry.
What is CLCS's market cap?
Cell Source, Inc. (CLCS) has a market capitalization of $14.40M as of 2025-03-31.
What exchange does CLCS trade on?
Cell Source, Inc. (CLCS) trades on the OTC.
Where is Cell Source, Inc. incorporated?
Cell Source, Inc. is incorporated in NV.